BSE Pharma Sector Regulatory Filings — May 12, 2026

12-05-2026

Dr. Reddy's Laboratories approved audited FY26 consolidated financial results (IFRS) showing revenues up 3% YoY to ₹335,933 million but profit down 26% YoY to ₹42,466 million, driven by higher impairments (₹3,519 million vs ₹1,693 million), elevated SG&A expenses (+14% YoY), and one-offs like ₹4,530 million Lenalidomide revenue reduction and CAR-T discontinuation losses. Global Generics revenue grew modestly 3% YoY to ₹299,033 million with flat-ish gross profit (-5% YoY), while Pharmaceutical Services & Active Ingredients revenue declined 3% YoY with gross profit down 35% YoY. The Board recommended a final dividend of ₹8 per share (record date July 10, 2026), approved the AGM for July 23, 2026, and made key governance changes including director re-appointments and auditor appointments.

• · Impairment of non-current assets FY26: ₹3,519 million (up 108% YoY from ₹1,693 million)
• · Basic EPS FY26: ₹51.48 (down from ₹67.88)
• · Short-term borrowings as of Mar 31, 2026: ₹59,135 million (up from ₹38,045 million)
• · Capex on PPE FY26: ₹23,326 million
• · Acquisition spend FY26: ₹3,152 million

12-05-2026

Dr. Reddy's Laboratories approved audited consolidated FY26 financial results (IFRS) showing revenues up 3.2% YoY to ₹335,933 million driven by Global Generics (+3.3% revenue), but gross profit declined 7% to ₹177,264 million, operating profit fell 30% to ₹50,551 million, and net profit dropped 26% to ₹42,466 million amid higher costs, ₹3,519 million impairments, and one-time charges like ₹4,530 million shelf stock adjustment in Q4. The Board recommended a final dividend of ₹8 per equity share (record date July 10, 2026) and approved the 42nd AGM on July 23, 2026, along with director re-appointments/appointments and auditor changes. Q4 revenues declined 12% YoY to ₹75,162 million while Pharmaceutical Services & Active Ingredients segment revenue was down 3% YoY for the year.

• · Re-appointment of Dr. K P Krishnan as Independent Director for second term Jan 7, 2027 to Jan 6, 2032.
• · Appointment of Mr. Srikanth Velamakanni as Independent Director Jul 1, 2026 to Jun 30, 2031.
• · Appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for 5 years post 42nd AGM.
• · Re-appointment of M/s Sagar & Associates as Cost Auditors for FY27.
• · Net cash from operating activities FY26: ₹56,755 million (up from ₹46,428 million).
• · Impairment loss of ₹914 million from Immutep Phase III study discontinuation.
• · Board meeting duration: 2:00 PM to 3:47 PM IST on May 12, 2026.

12-05-2026

Dr. Reddy's Laboratories approved audited FY26 consolidated financial results (IFRS) showing revenue growth of 3% YoY to ₹335,933 million from ₹325,535 million, primarily from Global Generics segment, but profit declined 26% YoY to ₹42,466 million from ₹57,245 million due to higher impairments (₹3,519 million vs ₹1,693 million), cost of revenues up 17%, and a ₹4,530 million revenue reversal from Lenalidomide shelf-stock adjustment. Gross profit fell 7% YoY to ₹177,264 million while Q4 revenue dropped 12% to ₹75,162 million. Recommended ₹8 final dividend per share (record date July 10, 2026), scheduled 42nd AGM on July 23, 2026, and approved board re-appointments, new director, auditors, and senior management elevation.

• · Cash and cash equivalents increased to ₹15,368 million from ₹14,654 million YoY.
• · Net cash from operating activities ₹56,755 million FY26 vs ₹46,428 million FY25.
• · Capital expenditure on PPE ₹23,326 million and intangibles ₹15,099 million FY26.
• · Re-appointment of Dr. K P Krishnan as Independent Director for 5 years from Jan 7, 2027.
• · Appointment of Mr. Srikanth Velamakanni as Independent Director from July 1, 2026 to June 30, 2031.
• · Appointment of Deloitte Haskins & Sells, LLP as Statutory Auditors for 5 years post-42nd AGM.

12-05-2026

Max Healthcare Institute Limited disclosed on May 12, 2026, the voting results of the postal ballot (e-voting from April 12 to May 11, 2026) approving the ordinary resolution for re-appointment of Mr. Narayan K. Seshadri as Non-Executive and Non-Independent Director, with 91.07% votes in favor (79,71,85,401 votes) out of 87,53,79,499 total valid votes cast, representing 89.95% turnout on 97,31,92,502 outstanding shares. However, 8.93% votes (7,81,94,098) were against the resolution, primarily from public institutions (12.21% against). The resolution was deemed passed on May 11, 2026, with the scrutinizer's report confirming compliance.

• · Cut-off date for voting eligibility: April 8, 2026
• · Postal Ballot Notice date: April 8, 2026
• · Remote e-voting period: April 12, 2026 (9:00 AM IST) to May 11, 2026 (5:00 PM IST)
• · Scrutinizer's report dated: May 12, 2026

12-05-2026

Pfizer Limited's Board of Directors, at its meeting on May 12, 2026, recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026. The company has fixed Friday, July 17, 2026, as the Record Date for determining entitlement to the final dividend pursuant to Regulation 42 of SEBI LODR Regulations, 2015. No comparative financial metrics or negative performance indicators were disclosed in this intimation.

• · Scrip Code on BSE: 500680
• · Scrip Symbol on NSE: PFIZER
• · CIN: L24231MH1950PLC008311

12-05-2026

Pfizer Limited's Board of Directors, at its meeting on May 12, 2026, recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026. The company has fixed Friday, July 17, 2026, as the Record Date for determining entitlement to this dividend, in compliance with Regulation 42 of SEBI (LODR) Regulations, 2015.

• · Scrip Code (BSE): 500680
• · Scrip Symbol (NSE): PFIZER
• · CIN: L24231MH1950PLC008311